OnePin Peptide Library · Metabolic
PEA (Palmitoylethanolamide)
Palmitoylethanolamide
Palmitoylethanolamide (PEA) is an endogenous fatty acid amide produced naturally in the body as part of the endocannabinoid system. It is structurally related to anandamide (the 'bliss' endocannabinoid) but binds different receptors. PEA is found in trace amounts in egg yolks, peanuts, and soybeans, but achieving therapeutic doses requires supplementation.,PEA was discovered in the 1950s when researchers noticed that egg yolk extract had anti-inflammatory effects. Italian research has been particularly active over the past 30 years, and PEA is approved as a 'food for special medical purposes' (FSMP) in the EU for chronic pain management. It is considered one of the safest pain/inflammation interventions available - completely non-addictive, no hepatotoxicity, no kidney toxicity, no GI bleeding risk.,Clinical evidence is strongest for chronic neuropathic pain, sciatica, fibromyalgia, post-shingles neuralgia, endometriosis, pelvic pain syndromes, and various inflammatory pain conditions. PEA can be used as a primary intervention for mild-moderate chronic pain or as an adjunct to reduce opioid/NSAID requirements in more severe pain. The micronized form (Normast, PeaPure) has dramatically better bioavailability than standard PEA and is what most clinical trials use.
Can be taken with or without food. Split dosing (2-3x daily) maintains steadier therapeutic levels. Effects develop over 2-4 weeks - not for acute pain. Loading dose (1,200mg/day for 2 weeks) then maintenance (600mg/day) is a common protocol.
Start here. Every protocol below is ordered lowest-first. Begin at the smallest effective dose, hold about a week to assess tolerance, and step up only if needed.
How it works
PEA's primary mechanism is activation of PPAR-alpha (peroxisome proliferator-activated receptor alpha), a nuclear receptor that regulates anti-inflammatory and pain-modulating gene expression. PPAR-alpha activation downregulates NF-kB signaling, reducing pro-inflammatory cytokine production (TNF-alpha, IL-6, IL-1).,Mast cell stabilization: PEA is one of the most effective natural mast cell stabilizers known. Mast cells release histamine, tryptase, and inflammatory mediators when activated - particularly relevant in allergic, inflammatory, and chronic pain conditions. PEA reduces mast cell degranulation and prevents excessive mast cell-mediated inflammation.,Endocannabinoid 'entourage effect': PEA is not a cannabinoid receptor agonist but enhances the activity of anandamide (the endogenous CB1 agonist) by inhibiting its breakdown enzyme FAAH. This indirectly increases endocannabinoid tone, contributing to analgesia and mood support.,TRPV1 receptor: PEA modulates TRPV1 (the capsaicin receptor) which is involved in pain transduction, particularly in inflammatory and neuropathic pain.,Microglial modulation: PEA reduces microglial activation in the CNS, decreasing neuroinflammation. This is particularly relevant for chronic pain that has 'centralized' (central sensitization) where peripheral pain has caused CNS inflammatory changes.,Glial cell function: PEA modulates glial-neuronal communication, important in chronic pain pathophysiology.
PEA's primary mechanism is activation of PPAR-alpha (peroxisome proliferator-activated receptor alpha), a nuclear receptor that regulates anti-inflammatory and pain-modulating gene expression. PPAR-alpha activation downregulates NF-kB signaling, reducing pro-inflammatory cytokine production (TNF-alpha, IL-6, IL-1).,Mast cell stabilization: PEA is one of the most effective natural mast cell stabilizers known. Mast cells release histamine, tryptase, and inflammatory mediators when activated - particularly relevant in allergic, inflammatory, and chronic pain conditions. PEA reduces mast cell degranulation and prevents excessive mast cell-mediated inflammation.,Endocannabinoid 'entourage effect': PEA is not a cannabinoid receptor agonist but enhances the activity of anandamide (the endogenous CB1 agonist) by inhibiting its breakdown enzyme FAAH. This indirectly increases endocannabinoid tone, contributing to analgesia and mood support.,TRPV1 receptor: PEA modulates TRPV1 (the capsaicin receptor) which is involved in pain transduction, particularly in inflammatory and neuropathic pain.,Microglial modulation: PEA reduces microglial activation in the CNS, decreasing neuroinflammation. This is particularly relevant for chronic pain that has 'centralized' (central sensitization) where peripheral pain has caused CNS inflammatory changes.,Glial cell function: PEA modulates glial-neuronal communication, important in chronic pain pathophysiology.
What to expect
Weeks 1-2: Subtle anti-inflammatory effects.
Evidence
Interactions & stacking
What's safe to combine, and what belongs in a separate pin.
Safe & synergistic
Keep separate
Pharmacokinetics
Storage. Store at room temperature (20-25C) in a cool, dry place. Protect from light and moisture. Capsules shelf-stable 2+ years.
Regulatory status
Approved as 'food for special medical purposes' (FSMP) in EU for chronic pain. Classified as a dietary supplement in the US - no prescription required. Wider availability and acceptance in Europe than US.
Put it to work
Calculate, log & track
Open PEA (Palmitoylethanolamide) straight into OnePin with your vial and dose pre-filled, then let it handle the syringe math and remind you before the vial runs out.
Open PEA (Palmitoylethanolamide) in the app →Go deeper
The guide & community
The complete PEA (Palmitoylethanolamide) walkthrough, real protocol discussion and coaching live inside the BlessUp community on Skool.
Join the community ↗